Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Telix Pharma
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
2024-11-19 06:24
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
2024-11-13 16:18
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
2024-11-04 06:07
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
2024-10-30 21:27
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
2024-10-24 06:02
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
2024-10-22 18:57
Telix Files Form 20-F Registration Statement for Nasdaq ADS
2024-10-18 05:32
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
2024-10-17 15:54
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
2024-10-08 04:00
First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
2024-10-04 04:00
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
2024-09-23 07:38
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
2024-09-18 05:00
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
2024-09-11 06:46
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
2024-09-04 06:57
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
2024-08-28 07:53
Telix Announces Reorganisation to Deliver on Strategic Priorities
2024-08-27 07:15
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
2024-08-22 17:04
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
2024-07-24 08:10
Telix Successfully Prices A$650 Million Convertible Bonds
2024-07-24 07:51
Telix Announces A$600 Million Convertible Bonds Offering
2024-07-23 16:35
1
2
3
4
5
7